Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Haas

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Foot & Ankle International|December 31, 2002
Toe flexor forces in dancers and non-dancersAneel Nihal, Jeffrey Goldstein, Judith Haas, et al.
Journal of Neurology|March 26, 2025
MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS RegisterAgni-Maria Konitsioti, Sarah Laurent, David Ellenberger, et al.
Magma (New York, N.Y.)|July 6, 2002
Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrationsFlorian Schubert, Frank Seifert, Clemens Elster, et al.
Multiple Sclerosis and Related Disorders|September 27, 2019
Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studiesJudith Haas, Douglas Jeffery, Diego Silva, et al.
Therapeutic Advances in Neurological Disorders|October 8, 2020
Relapsing and progressive MS: the sex-specific perspectivePaulus Stefan Rommer, David Ellenberger, Kerstin Hellwig, et al.
Neurological Research and Practice|November 17, 2024
MS brain health quality standards: a survey on the reality in clinical practice in GermanyIsabel Voigt, Katja Akgün, Hernan Inojosa, et al.
Frontiers in Neurology|March 25, 2021
Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS PatientsTjalf Ziemssen, Holger Albrecht, Judith Haas, et al.
Multiple Sclerosis and Related Disorders|September 27, 2020
Is benign MS really benign? What a meaningful classification beyond the EDSS must take into considerationDavid Ellenberger, Peter Flachenecker, Judith Haas, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 24, 2017
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEATjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 8, 2025
Paediatric-onset multiple sclerosis: demographics, symptoms and disease progressionDavid Ellenberger, Peter Flachenecker, Judith Haas, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Foot & Ankle International|December 31, 2002
Toe flexor forces in dancers and non-dancersAneel Nihal, Jeffrey Goldstein, Judith Haas, et al.
Journal of Neurology|March 26, 2025
MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS RegisterAgni-Maria Konitsioti, Sarah Laurent, David Ellenberger, et al.
Magma (New York, N.Y.)|July 6, 2002
Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrationsFlorian Schubert, Frank Seifert, Clemens Elster, et al.
Multiple Sclerosis and Related Disorders|September 27, 2019
Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studiesJudith Haas, Douglas Jeffery, Diego Silva, et al.
Therapeutic Advances in Neurological Disorders|October 8, 2020
Relapsing and progressive MS: the sex-specific perspectivePaulus Stefan Rommer, David Ellenberger, Kerstin Hellwig, et al.
Neurological Research and Practice|November 17, 2024
MS brain health quality standards: a survey on the reality in clinical practice in GermanyIsabel Voigt, Katja Akgün, Hernan Inojosa, et al.
Frontiers in Neurology|March 25, 2021
Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS PatientsTjalf Ziemssen, Holger Albrecht, Judith Haas, et al.
Multiple Sclerosis and Related Disorders|September 27, 2020
Is benign MS really benign? What a meaningful classification beyond the EDSS must take into considerationDavid Ellenberger, Peter Flachenecker, Judith Haas, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 24, 2017
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEATjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 8, 2025
Paediatric-onset multiple sclerosis: demographics, symptoms and disease progressionDavid Ellenberger, Peter Flachenecker, Judith Haas, et al.
Pageof 5